The Anti-dsDNA antibody test, particularly the Farr assay, is a highly specific diagnostic tool pivotal in the evaluation and management of systemic lupus erythematosus (SLE), a complex autoimmune disorder. Double-stranded DNA (dsDNA) antibodies are a type of antinuclear antibody (ANA) that specifically target the DNA within the cell nucleus. These antibodies are considered one of the hallmark indicators of SLE, with their presence being a key criterion in the diagnosis of the disease.
The Farr assay, a radioimmunoassay, is renowned for its high specificity in detecting anti-dsDNA antibodies. This assay utilizes radiolabeled DNA to capture antibodies from a patient's serum. The bound antibodies are then measured, providing a quantitative assessment of the anti-dsDNA antibodies present. A positive Farr assay is strongly indicative of SLE, as these antibodies are rarely found in healthy individuals or those with other autoimmune disorders.
The presence and levels of anti-dsDNA antibodies, as determined by the Farr assay, are not only critical in confirming a diagnosis of SLE but also invaluable in monitoring the disease's activity and severity. Fluctuations in the levels of these antibodies often correlate with disease flare-ups and remissions, making them a useful marker in assessing response to treatment and guiding clinical decision-making.
For patients suspected of having SLE, or for those managing the condition, the Anti-dsDNA antibody test via the Farr assay is a crucial component of the diagnostic and monitoring process. It provides clarity in distinguishing SLE from other autoimmune conditions and helps in tailoring individualized treatment plans.
Anti-dsDNA ab (Farr Assay)
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.